Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: Cancer Res. 2012 Jun 27;72(16):4154–4164. doi: 10.1158/0008-5472.CAN-11-2848

FIGURE 4. Simultaneous disruption of EGFR and either CK1 or CK2 signaling act synergistically to inhibits NSCLC cell expansion.

FIGURE 4

A) H322C cells expressing a negative control shRNA (shScrbl) or shRNAs targeting CSNK1A1 (CK1α) were treated with DMSO or 500 nM gefitinib for 4 days, followed by replating without drug for 3 days. Viable cells were counted. B) As in A, except H322C cells expressed either shScrbl or shRNAs targeting CSNK2A1 (CK2α). C) H322C cells and HCC4006 were treated in triplicate with DMSO or gefitinib (500 nM for H322C; 20 nM for HCC4006) and/or pyrvinium (Pyr; 10 nM for H322C; 2 nM for HCC4006) for 4 days and then replated without drugs for colony forming assays. For A–C, ** indicates p<0.01, and *** p<0.001. D) Proposed model.